NICE backs Ocrevus for PPMS in England - but with caveats

07:51 EDT 9 May 2019 | pharmaphorum

Patients with a severe progressive form of multiple sclerosis will get access to the first licensed treatment for the condition after NICE recommended regular NHS funding for Roche's Ocrevus, although there are still restrictions on who will receive ...

Original Article: NICE backs Ocrevus for PPMS in England - but with caveats


More From BioPortfolio on "NICE backs Ocrevus for PPMS in England - but with caveats"

Quick Search


Relevant Topics

Spinal Cord Disorders
The spinal cord is a bundle of nerves that runs down the middle of the back which carry signals back and forth between the body and brain. It is protected by vertebrae, which are the bone disks that make up the spine. An accident that damages the verte...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...